CDEK
← All drugs Report issue

autologous plasma

Biologicalexperimental

Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of plasma protein derived from whole blood, centrifuged to remove red blood cells but retaining platelets. Though promoted for treating various medical conditions, evidence of its benefits was mixed as of 2020, showing effectiveness in certain conditions and ineffectiveness in others. — Wikipedia

Clinical trial activity

16 trials · 28 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
5
Phase 3
5
Phase 4
1

Earliest trial started Oct 1, 2009 (NCT01131455)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • BloodTissue restoration

    Blood tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • autologous concentrated plasma
  • autologous conditioned plasma
  • autologous freeze dried plasma
  • autologous plasma

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05629338Phase 1Dec 1, 2022Velico Medical
NCT05182515Phase 3Dec 22, 2021Centre Hospitalier St Anne, University of Paris
NCT05093075Phase 2Oct 31, 2021Canadian Institutes of Health Research (CIHR), Health Sciences Centre Foundation, Manitoba, McMaster University, University of Manitoba, University of Toronto
NCT04581382Early Phase 1 (Phase 1)Dec 15, 2020Mayo Clinic, National Cancer Institute (NCI)
NCT04431999Phase 3Sep 30, 2020Direction Centrale du Service de Santé des Armées, Ecoles militaires de santé de Lyon-Bron, Floralis, TIMC-IMAG
NCT04973488Phase 2/Phase 3 (Phase 3)Jul 25, 2020University of Medicine and Pharmacy Victor Babes Timisoara
NCT04685655N/AJan 7, 2020University of Heidelberg
NCT03889925Phase 2/Phase 3 (Phase 3)Mar 15, 2019Andrews Research & Education Foundation
NCT03768115Early Phase 1 (Phase 1)Nov 1, 2018Government of Singapore, Singapore National Eye Centre
NCT03353597Phase 1/Phase 2 (Phase 2)May 15, 2018Fountain Labs, Inc.
NCT02930226Phase 1Oct 1, 2016United States Army, University of Cincinnati
NCT01789762Phase 4May 1, 2013Etablissement Français du Sang, University of Grenoble
NCT02417987N/AMay 1, 2012University of Copenhagen
NCT01414764Phase 3May 1, 2011Arthrex, Inc., University of Western Australia
NCT01170312N/ASep 1, 2010Arthrex, Inc., McMaster University
NCT01131455N/AOct 1, 2009Columbia Orthopaedic Group, LLP
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (28)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Arthrex, Inc.For profit2022010
McMaster UniversityAcademic/Hospital2122010
Andrews Research & Education FoundationAcademic/Hospital1112019
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012021
Centre Hospitalier St AnneAcademic/Hospital1112021
Columbia Orthopaedic Group, LLPAcademic/Hospital1112009
Direction Centrale du Service de Santé des ArméesGovernment1112020
Ecoles militaires de santé de Lyon-BronAcademic/Hospital1012020
Etablissement Français du SangAcademic/Hospital1112013
FloralisFor profit1012020
Fountain Labs, Inc.For profit1112018
Government of SingaporeGovernment1012018
Health Sciences Centre Foundation, ManitobaAcademic/Hospital1012021
Mayo ClinicAcademic/Hospital1112020
National Cancer Institute (NCI)Government1012020
Singapore National Eye CentreAcademic/Hospital1112018
TIMC-IMAGAcademic/Hospital1012020
United States ArmyGovernment1112016
University of CincinnatiAcademic/Hospital1012016
University of CopenhagenAcademic/Hospital1112012
28 organizations
Page 1 / 2